SUNPHARMA

Sun Pharmaceutical Industries Share Price

₹1,866.1
+ 3.15 (0.17%)
  • Advice
  • Hold
18 September, 2024 02:38 BSE: 524715 NSE: SUNPHARMA ISIN: INE044A01036

Start SIP in Sun Pharmaceutical Industries

Start SIP

Sun Pharmaceutical Industries Performance

Day Range

  • Low 1,859
  • High 1,870
₹ 1,866

52 Week Range

  • Low 1,068
  • High 1,873
₹ 1,866
  • Open Price1,863
  • Previous Close1,863
  • Volume738265

Sun Pharmaceutical Industries Chart

  • Over 1 Month + 7.08%
  • Over 3 Month + 23.09%
  • Over 6 Month + 20.53%
  • Over 1 Year + 62.3%

Sun Pharmaceutical Industries Key Statistics

P/E Ratio 43.1
PEG Ratio 1.9
Market Cap Cr
Price to Book Ratio 6.7
EPS 12.7
Dividend 0.7
Relative Strength Index 73.84
Money Flow Index 63.27
MACD Signal 38.95
Average True Range 26.63

Sun Pharmaceutical Industries Investment Rating

  • Master Rating:
  • Sun Pharm.Industries has an operating revenue of Rs. 49,208.76 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 23% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 21% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 13% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 64 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Sun Pharmaceutical Industries Financials
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 4,4985,6394,9045,0964,3835,801
Operating Expenses Qtr Cr 3,7373,7463,7153,7103,5173,588
Operating Profit Qtr Cr 7611,8941,3591,3869492,361
Depreciation Qtr Cr 370393400393415412
Interest Qtr Cr 216218215194158161
Tax Qtr Cr 2053430189-9
Net Profit Qtr Cr 238868721889381-1,021
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 20,74121,091
Operating Expenses Annual Cr 14,68814,339
Operating Profit Annual in Cr 5,5886,473
Depreciation Cr 1,6011,601
Interest Annual Cr 784472
Tax Annual Cr 59150
Net Profit Annual Cr 2,8581,691
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr -292507
Cash from Investing Activity Annual Cr -263-705
Cash from Financing Annual Activity Cr 474169
Net Cash Flow Annual Cr -81-29
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 23,69423,748
Fixed Assets Annual Cr 8,5039,565
Total Non Current Assets Annual Cr 26,11024,522
Total Current Assets Annual Cr 14,95416,465
Total Assets Annual Cr 41,06540,987
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 9999
ROE Annual % 127
ROCE Annual % 1216
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 3032
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 12,65311,98312,15712,19211,78510,726
Operating Expenses Qtr Cr 9,0458,9488,9049,0138,6098,129
Operating Profit Qtr Cr 3,6083,0353,4773,1793,3322,802
Depreciation Qtr Cr 655650622633651672
Interest Qtr Cr 627435498193
Tax Qtr Cr 552149432390468223
Net Profit Qtr Cr 2,8362,6552,5242,3762,0231,984
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 49,85144,520
Operating Expenses Annual Cr 35,47432,239
Operating Profit Annual in Cr 13,02311,647
Depreciation Cr 2,5572,529
Interest Annual Cr 238172
Tax Annual Cr 1,439848
Net Profit Annual Cr 9,5768,474
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 12,1354,959
Cash from Investing Activity Annual Cr -690-7,944
Cash from Financing Annual Activity Cr -6,7102,376
Net Cash Flow Annual Cr 4,735-608
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 63,66755,995
Fixed Assets Annual Cr 19,96620,681
Total Non Current Assets Annual Cr 41,98840,860
Total Current Assets Annual Cr 43,47539,883
Total Assets Annual Cr 85,46380,744
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 280247
ROE Annual % 1515
ROCE Annual % 1716
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 3028

Sun Pharmaceutical Industries Technicals

EMA & SMA

Current Price
₹1,866.1
+ 3.15 (0.17%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹1,817.10
  • 50 Day
  • ₹1,740.81
  • 100 Day
  • ₹1,655.86
  • 200 Day
  • ₹1,533.00
  • 20 Day
  • ₹1,817.45
  • 50 Day
  • ₹1,729.27
  • 100 Day
  • ₹1,618.22
  • 200 Day
  • ₹1,526.76

Sun Pharmaceutical Industries Resistance and Support

PIVOT
₹1,865.
Resistance
First Resistance 1,870.75
Second Resistance 1,875.40
Third Resistance 1,881.15
RSI 73.84
MFI 63.27
MACD Single Line 38.95
MACD 38.21
Support
First Support 1,860.35
Second Support 1,854.60
Third Supoort 1,849.95

Sun Pharmaceutical Industries Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 766,702 51,691,049 67.42
Week 1,602,131 95,374,835 59.53
1 Month 1,865,493 118,421,490 63.48
6 Month 2,580,253 153,783,092 59.6

Sun Pharmaceutical Industries Result Highlights

Sun Pharmaceutical Industries Synopsis

NSE-Medical-Generic Drugs

Sun Pharma. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 20275.17 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2024. Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050.
Market Cap 446,984
Sales 20,307
Shares in Float 110.37
No of funds 1141
Yield 0.94
Book Value 18.86
U/D Vol ratio 1.6
LTDebt / Equity 47
Alpha 0.15
Beta 0.43

Sun Pharmaceutical Industries Shareholding Pattern

Owner NameJun-24Mar-24Dec-23Sep-23
Promoters 54.48%54.48%54.48%54.48%
Mutual Funds 12.78%12.21%12.93%13.07%
Insurance Companies 4.91%5.06%5.02%5.06%
Foreign Portfolio Investors 17.23%17.72%17.08%16.78%
Financial Institutions/ Banks 0.04%0.02%0.04%0.06%
Individual Investors 5.57%5.44%5.41%5.55%
Others 4.99%5.07%5.04%5%

Sun Pharmaceutical Industries Management

Name Designation
Mr. Dilip S Shanghvi Chairman & Managing Director
Mr. Aalok D Shanghvi Whole Time Director
Mr. Sudhir V Valia Non Exe.Non Ind.Director
Dr. Pawan Goenka Lead Independent Director
Mr. Rama Bijapurkar Independent Director
Mr. Gautam Doshi Independent Director
Mr. Sanjay Asher Independent Director
Mr. Rolf Hoffmann Independent Director

Sun Pharmaceutical Industries Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Sun Pharmaceutical Industries Corporate Action

Date Purpose Remarks
2024-08-01 Quarterly Results
2024-05-22 Audited Results & Final Dividend
2024-01-31 Quarterly Results & Interim Dividend
2023-11-01 Quarterly Results
2023-08-03 Quarterly Results
Date Purpose Remarks
2024-07-12 FINAL Rs.5.00 per share(500%)Final Dividend
2024-02-09 INTERIM Rs.8.50 per share(850%)Interim Dividend
2023-07-28 FINAL Rs.4.00 per share(400%)Final Dividend
2023-02-08 INTERIM Rs.7.50 per share(750%)Interim Dividend
2022-08-22 FINAL Rs.3.00 per share(300%)Final Dividend

Sun Pharmaceutical Industries MF Shareholding

About Sun Pharmaceutical Industries

Active Pharma Ingredients (APIs) & variety of branded & generic formulations are produced, developed, & marketed by Sun Pharmaceuticals Industries Ltd. With global presence in trading & other ancillary activities, the corporation & its subsidiaries operate multiple manufacturing facilities across the globe, catering to the global market. It is India's biggest pharmaceutical corporation. Product Offerings: company manufactures a wide range of specialty & generic medications to address a variety of acute & chronic medical conditions. Generics, branded generics, specialist, hard-to-make technology-intensive pharmaceuticals, antiretrovirals, APIs, & intermediates are all part of its product line. It provides medications in every possible dose form, including liquids, tablets, sprays, ointments, creams, injectables, & capsules.

Indian Branded Generics: Largest Pharma business in India with 8.3% market share; Approximately 32% of revenues in FY23. Prescriptions with 12 classes of prescribers rank it first as well. In India, Sun Pharma leads the market in the chronic category. In India's top 300 pharmaceutical brands, it has 32 brands. Among other specialties, gastroenterology makes up 12%, neuropsychiatry 16%, & cardiology 18%.

US Business (~31% of revenues): This company ranks second in the US dermatology industry by prescriptions & joined the US pharma market in 1997. In terms of US generics, it ranks tenth. There were 616 ANDAs & 67 NDAs filed as of Q1FY24, & 519 ANDAs & 54 NDAs that had been authorized for a variety of therapies.

13 NDAs & 97 ANDAs are awaiting USFDA clearance. OTC, generics, & specialty markets are areas where corporations are well-represented. Liquids, creams, ointments, gels, sprays, injectables, tablets, capsules, drug-device combinations, & other products are sold by the company.
 

Sun Pharmaceutical Industries FAQs

What is Share Price of Sun Pharmaceutical Industries ?

Sun Pharmaceutical Industries share price is ₹1,866 As on 18 September, 2024 | 02:24

What is the Market Cap of Sun Pharmaceutical Industries ?

The Market Cap of Sun Pharmaceutical Industries is ₹447739.9 Cr As on 18 September, 2024 | 02:24

What is the P/E ratio of Sun Pharmaceutical Industries ?

The P/E ratio of Sun Pharmaceutical Industries is 43.1 As on 18 September, 2024 | 02:24

What is the PB ratio of Sun Pharmaceutical Industries ?

The PB ratio of Sun Pharmaceutical Industries is 6.7 As on 18 September, 2024 | 02:24

What is the future of Sun Pharmaceutical Industries (Sun Pharma)?

Sun Pharmaceutical Industries (Sun Pharma) has an operating revenue of INR 36,704.43 Cr. on a trailing 12-month basis. Annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay. Institutional holding has gone up in the last reported quarter is a positive sign. Analyst Recommendation on Sun Pharmaceutical Industries (Sun Pharma): HOLD

Who is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma)?

Dilip Shanghvi is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma).

What is the ROE of Sun Pharmaceutical Industries (Sun Pharma)?

The ROE of Sun Pharmaceutical Industries (Sun Pharma) is 6% which is fair but needs improvement.

Is Sun Pharmaceutical Industries (Sun Pharma) Debt to Equity Ratio?

Sun Pharmaceutical Industries (Sun Pharma) has a reasonable debt to equity of 2%, which signals a healthy balance sheet.

What is the PE ratio of Sun Pharmaceutical Industries (Sun Pharma)?

The PE ratio of Sun Pharmaceutical Industries (Sun Pharma) is 81.5.

What are the most important metrics that can help to analyse the share price of Sun Pharmaceuticals Industries Ltd?

Metrics for analyzing sun pharma share price include: P/E Ratio, ROE, Profit Growth, as it Shows historical earnings growth.

How can you buy shares from Sun Pharmaceuticals Industries Ltd ?

To buy Sun Pharmaceuticals Industries Ltd shares, open a 5paisa account, fund it, search for Sun Pharmaceuticals Industries Ltd , place buy order, & confirm.

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form